publication date: Aug 6, 2021
author/source: Creative Diagnostics
Creative Diagnostics launch a variety of lentiviral SARS-CoV-2 pseudovirus from a wide range of coronavirus species.
As a global leading supplier of of raw materials, antibodies, and reagents for bio-technology industry, Creative Diagnostics recently launched a variety of lentiviral SARS-CoV-2 pseudovirus from a wide range of coronavirus species. Different vectors can be used to express different reporters such as EGFP or luciferase, allowing the monitoring of viral entry into host cells by a variety of means.
Various Products are included in this release, such as the Pseudotyped Luciferase rSARS-CoV-2 Spike Luciferase(COV-PS01), Pseudotyped GFP rSARS-CoV-2 Spike(COV-PS02), Pseudotyped rSARS-CoV-2 Spike (COV-PS03), Pseudotyped Luciferase Lentivirus Luciferase(COV-PSL1), and Pseudotyped GFP Lentivirus(COV-PSG2). In addition, Creative Diagnostics’ research team has been working diligently to stay abreast of these new developments and are currently developing a serial of Lentiviral SARS-CoV-2 Mutation Pseudovirus.
Pseudotyped Luciferase/GFP rSARS-CoV-2 Spike display antigenically correct spike protein pseudotyped (Wuhan-Hu-1 strain or D614G mutant) on replication-incompetent virus particles that contain a heterologous lentiviral (HIV) core and are capable of a single round of infection and carry a genome that expresses either a GFP or luciferase optical reporter gene upon infection. Pseudotyped Luciferase/GFP rSARS-CoV-2 Spike are produced in HEK-293T cells using three separate plasmids, encoding the spike protein, a lentiviral gag polyprotein, and a reporter gene and can be used to test the ability of serum, antibodies, and drugs to neutralize the infectivity of SARS-CoV- 2 spike protein. Pseudotyped Luciferase/GFP VSV is designed as a control for Creative Diagnostics’ Pseudotyped Luciferase/GFP rSARS-CoV-2 Spike to test for non-specific factors that affect virus infectivity. The VSV-G protein confers the Pseudovirus with a high level of single cycle infectivity due to its broad tropism.
Creative Diagnostics provides a full range of ready-to-use wild-type and newly emerged mutant SARS-CoV-2 pseudotyped lentiviruses to study the interaction between SARS-CoV-2 spike protein and human ACE2 in a physiologically relevant context. Various products are available to researchers such as Pseudotyped Luciferase rSARS-CoV-2 Spike (UK Variant B.1.1.7), Pseudotyped GFP rSARS-CoV-2 Spike, Japanese/Brazilian Variant (P.1), Pseudotyped Luciferase rSARS-CoV-2 Spike (South African Variant 501Y.V2), Pseudotyped GFP rSARS-CoV-2 Spike, B.1.617 India, and Pseudotyped Luciferase rSARS-CoV-2 Spike, Californian L452R Variant (B.1.427/B.1.429).
“SARS-CoV-2 Pseudovirus are used to test the ability of serum, antibodies, and drugs to neutralize the infectivity of SARS-CoV-2 spike protein.” explained Dr. Jessica Waldorf, chief scientific officer of R&D department of Creative Diagnostics. “We are working with our customers to fight against the emerging variants in the pandemic by continuously providing reliable solutions and research tools for their studies. The new lentiviral SARS-CoV-2 pseudovirus allows us to support our clients’ programs and better face SARS-CoV-2 variants.”
If you can’t a find a suitable pseudovirus or want to know more details lentiviral SARS-CoV-2 pseudovirus or other research materials, please visit Creative Diagnostics
About Creative Diagnostics
Creative Diagnostics is a leading manufacturer and supplier of antibodies, viral antigens, innovative diagnostic components and critical assay reagents. It also provides contract biologic R&D and manufacturing services to the diagnostic manufacturers along with GMP biologics manufacturing for the biopharmaceutical market. It aims to provide a trusted source for all researchers’ assay development and manufacturing needs.